z-logo
open-access-imgOpen Access
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Author(s) -
H. Borghaei,
L. Paz-Ares,
Leora Horn,
David R. Spigel,
Martin Steins,
Neal Ready,
Laura Q.M. Chow,
Everett E. Vokes,
Enriqueta Felip,
Esther Holgado,
Fabrice Barlési,
M. Kohlhufl,
Óscar Arrieta,
M. Burgio,
Jérôme Fayette,
H. Lena,
Elena Poddubskaya,
David E. Gerber,
Scott Gettinger,
Charles M. Rudin,
Naiyer A. Rizvi,
L. Crina,
George R. Blumenschein,
Scott Antonia,
Cécile Dorange,
Christopher Harbison,
F. Graf Finckenstein,
Julie R. Brahmer
Publication year - 2015
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1507643
Subject(s) - medicine , docetaxel , nivolumab , lung cancer , oncology , cancer , immunotherapy
Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom